dopamine

dopamine is a critical catecholamine neurotransmitter and hormone that plays fundamental roles in the central nervous system, peripheral nervous system, and endocrine system. It was first synthesized in 1910 by George Barger and James Ewens at the Wellcome Laboratories in London, and its significance as a neurotransmitter was later established by the pioneering work of Arvid Carlsson, who was awarded the Nobel Prize in Physiology or Medicine in 2000. This chemical messenger is integral to regulating a vast array of physiological processes, from motor control and reward processing to modulating blood pressure and gastrointestinal activity.

Chemical properties and biosynthesis

Dopamine is an organic compound belonging to the family of phenethylamines and catecholamines, characterized by a benzene ring with two adjacent hydroxyl groups and an ethylamine side chain. Its biosynthesis occurs primarily in neurons of the brain and in chromaffin cells of the adrenal medulla. The precursor amino acid tyrosine is converted to L-DOPA by the enzyme tyrosine hydroxylase, which is the rate-limiting step in the pathway. L-DOPA is then rapidly decarboxylated to dopamine by the enzyme aromatic L-amino acid decarboxylase, a process that requires the cofactor pyridoxal phosphate. This synthesis pathway is a key branch point, as dopamine can be further metabolized to norepinephrine and epinephrine by the actions of dopamine beta-hydroxylase and phenylethanolamine N-methyltransferase, respectively.

Neurotransmission and receptors

As a neurotransmitter, dopamine operates within specific neural pathways, including the nigrostriatal pathway, mesolimbic pathway, and mesocortical pathway. Its action is terminated primarily through reuptake into the presynaptic neuron via the dopamine transporter and subsequent enzymatic breakdown by monoamine oxidase and catechol-O-methyltransferase. Dopamine exerts its effects by binding to and activating a family of G protein-coupled receptors, which are classified into two main families: D1-like receptors (D1 and D5) and D2-like receptors (D2, D3, and D4). These receptors are coupled to different intracellular signaling cascades; D1-like receptors typically stimulate adenylyl cyclase, while D2-like receptors inhibit it, leading to diverse and often opposing physiological effects in regions like the basal ganglia and prefrontal cortex.

Functions in the brain and body

In the brain, dopamine is famously involved in the reward system, mediating feelings of pleasure and motivation, a concept heavily studied through experiments involving intracranial self-stimulation. It is crucial for voluntary movement coordination, primarily through the nigrostriatal pathway projecting from the substantia nigra to the striatum. Dopamine also modulates executive functions, attention, and working memory in the prefrontal cortex, and influences prolactin secretion from the anterior pituitary gland. Peripherally, dopamine acts as a paracrine messenger, affecting renal function by promoting vasodilation and natriuresis, and plays a role in the sympathetic nervous system's regulation of heart rate and vascular resistance.

Clinical significance and disorders

Dysregulation of dopaminergic systems is central to several major neurological and psychiatric disorders. The profound loss of dopaminergic neurons in the substantia nigra is the primary pathological hallmark of Parkinson's disease, leading to its characteristic bradykinesia, rigidity, and tremor. Conversely, hyperactivity or hypersensitivity of dopaminergic transmission, particularly in the mesolimbic pathway, is strongly implicated in the positive symptoms of schizophrenia, such as hallucinations and delusions. Other conditions linked to dopamine dysfunction include attention deficit hyperactivity disorder, restless legs syndrome, and addiction, with substances like cocaine and amphetamine exerting their potent effects by dramatically increasing synaptic dopamine levels.

Pharmacology and therapeutic uses

Pharmacological manipulation of dopamine signaling is a cornerstone of modern neuropsychiatry. The most direct therapy for Parkinson's disease is administration of the metabolic precursor levodopa, which is converted to dopamine in the brain, often combined with carbidopa to prevent peripheral conversion. Dopamine agonists like pramipexole and ropinirole directly stimulate dopamine receptors, while monoamine oxidase B inhibitors like selegiline slow its breakdown. In psychiatry, antipsychotic medications, also known as neuroleptics, primarily function as dopamine antagonists, blocking D2 receptors; examples include haloperidol and chlorpromazine. Drugs like methylphenidate, used for ADHD, inhibit the dopamine transporter to increase extracellular dopamine, and apomorphine is used as a rescue therapy for severe "off" episodes in Parkinson's disease. Category:Neurotransmitters Category:Catecholamines Category:Biogenic amines